Single-center experience in percutaneous closure of arterial duct with Amplatzer duct Occluder II additional sizes.

Objectives: This study aimed to report a large, single-center experience of percutaneous arterial duct (AD) closure using Amplatzer Duct Occluder II Additional Sizes device (ADO II-AS)(St. Jude Medical Corp, St. Paul, MN, USA).Background: Transcatheter closure of AD remains challenging in low body weight patients and those who have a persisting shunt following a previous attempt at interventional closure. Recent technical advances in device design may address these issues.Methods: From May 2011 to April 2016, 109 patients underwent attempted percutaneous closure of AD with ADO II-AS at our Institution. Mean age and weight were 4.88.1 years (range 0-48) and 21.420.6 kg (range 3-93), respectively. Fifteen patients (13.8%) were 6 kg (age 3.5 +/- 2.0 months; weight 4.7 +/- 1.1 kg). Arterial duct morphology was type A in 62 (57%), type B in 1 (1%), type C in 32 (29%), type D in 7 (6%) and type E in 6 patients (6%), respectively. Arterial approach was used to negotiate and deploy the occluding device in 103 patients (94.5%). Results: AD diameter was 2.2 +/- 0.6 (range 1.5-4.5) resulting in QP/QS of 1.9 +/- 0.7 (range 1-3.3). Mean pulmonary artery pressure and PA/aortic pressure ratio were 19.3 +/- 5.0 mm Hg (range 12-38) and 0.34 +/- 0.14 (range 0.14-0.95), respectively. Successful device deployment was achieved in 107 patients (98.2%). Neither procedural morbidity nor mortality was recorded. Immediate, 24h and mid-term (30 +/- 17 months) complete occlusion was recorded in 71%, 98.1%, and 100% of patients, respectively.ConclusionIn our experience, trans-catheter closure of AD of different sizes and morphologies using ADO II-AS is highly feasible, safe and effective also in challenging anatomic/clinical settings. (C) 2016 Wiley Periodicals, Inc.